Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Cholangiocarcinoma 5 Urinary Bladder Neoplasms 3 Acrocephalosyndactylia 3 Stomach Neoplasms 2 Glioblastoma 2 Breast Neoplasms 2 Uterine Cervical Neoplasms 1 Upper Tract Urothelial Carcinomas 1 Tumor With Alterations of the FGF-R 1 Squamous Cell Carcinoma of Head and Neck 1 Renal Pelvis and Ureter Urothelial Carcinoma 1 Rectal Neoplasms 1 Papillomavirus Infections 1 Pancreatic Neoplasms 1 Oncogenic osteomalacia 1 Neoplasms 1 Neoplasm Metastasis 1 Nasopharyngeal Neoplasms 1 Melanoma 1 Lung Neoplasms 1 Liver Neoplasms 1 Hypophosphatemia 1 Hematologic Neoplasms 1 Glioma 1 Colonic Neoplasms 1 Central Nervous System Neoplasms 1 Advanced Gastrointestinal Stromal Tumor (GIST) 1

Interventions

pembrolizumab 287 Nivolumab 258 Ipilimumab 236 aldesleukin 134 Cyclophosphamide 134 Interleukin-2 104 Temozolomide 75 Dacarbazine 74 trametinib 70 Vemurafenib 69 fludarabine 67 dabrafenib 65 fludarabine phosphate 61 sargramostim 44 binimetinib 44 Radiosurgery 44 Biopsy 43 Paclitaxel 42 Bevacizumab 42 incomplete Freund's adjuvant 39 encorafenib 37 Radiotherapy 36 Cisplatin 36 CTLA-4 Antigen 36 atezolizumab 35 Carboplatin 35 cobimetinib 32 Magnetic Resonance Spectroscopy 32 Introns 30 Specimen Handling 29

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Melanoma × infigratinib × Clear all

NCT02159066 2024-03-05

LOGIC-2

Pfizer

Phase 2 Completed

158 enrolled 40 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡